FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2565656247> ?p ?o ?g. }

• W2565656247 abstract "Abstract Abstract 3917 Treatment with the anti-CD20 monoclonal antibody rituximab (RTX) has become the standard-of-care for the treatment of B-cell non-Hodgkin lymphoma (NHL). Despite revolutionizing NHL therapy, many patients demonstrate resistance de novo or develop resistance to RTX following treatment with RTX-containing regimens and/or RTX-based maintenance schedules. Ofatumumab (OFA) is a new 2nd-generation CD20 mAb targeting a novel membrane-proximal epitope on the CD20 antigen. OFA has been FDA-approved for the treatment of fludarabine- and alemtuzumab-refractory CLL and is being evaluated in several clinical trials in NHL. To better define OFA's activity, we conducted pre-clinical studies comparing OFA vs. RTX in a panel of RSCL, RRCL, primary lymphoma cells (n=10), and in a lymphoma xenograft model. Antibody-dependant cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) assays were performed to evaluate differences in activity between RTX and OFA. Lymphoma cells were labeled with 51Cr prior to incubation with RTX or OFA (1 or 10 mg/ml) plus effector cells or human serum respectively. 51Cr-release was measured and the percentage of lysis was calculated. In addition, we evaluated the effect of OFA in the cytotoxic effects of chemotherapy agents (doxorubicin, cisplatin and vincristine) and correlated OFA anti-tumor activity to biomarkers known to affect RTX activity (i.e. CD20, CD55, and CD59 surface expression) using qualitative and quantitative flow cytometry. Competitive binding assays were performed using fluorescent-labeled RTX or OFA. OFA was more potent than RTX in elucidating effective CDC at the doses tested not only in RSCL, but also in all RRCL and in primary tumor cells derived from patients with B-cell lymphoma. OFA and RTX were equally effective in ADCC assays. In RSCL and RRCL, there was a linear decrease in sensitivity to RTX (as evaluated by CDC) with decreasing CD20 expression; in contrast, OFA maintained activity even at the lowest levels of CD20 expression. Furthermore, OFA was active despite high levels of CD59 and CD55. OFA had a higher affinity for CD20 than RTX in RSCL. Pre-incubation of RSCL and RRCL with OFA enhanced the anti-tumor activity of chemotherapy agents as determined by alamar blue reduction. Severe combined immunodeficiency (SCID) mice were inoculated via tail vein with Raji cells (day 0) and assigned to observation versus 4 doses of either OFA or RTX (1 or 10mg/kg/dose). The end point of the study was overall survival. Statistical analysis was performed with Kaplan-Meier survival curves and P values calculated by log-rank test. OFA was more effective in controlling in vivo lymphoma growth than RTX. The median survival for animals treated with OFA (1 or 10mg/kg/dose) [73 days and 78 days] was longer than those treated with RTX [56 days and 61 days] (P=0.04 and P=0.04 respectively). Our data suggest that OFA is more potent than RTX not only in RTX-sensitive but also in RTX-resistant models and potentiates the anti-tumor activity of chemotherapy agents commonly used in the treatment of B-cell NHL. We are continuing our research into defining the mechanisms by which OFA increases the lymphoma cell sensitivity threshold to chemotherapy agents and to novel target-specific small molecule inhibitors. Disclosures: Barth: Genmab: Research Funding. Hernandez-Ilizaliturri:Genmab: Research Funding. Mavis:Genmab: Research Funding. Gibbs:Genmab: Research Funding. Deeb:Genmab: Research Funding. Czuczman:Genmab: Research Funding." @default.
• W2565656247 created "2017-01-06" @default.
• W2565656247 creator A5001862108 @default.
• W2565656247 creator A5003033577 @default.
• W2565656247 creator A5024574848 @default.
• W2565656247 creator A5025865972 @default.
• W2565656247 creator A5028606740 @default.
• W2565656247 creator A5038651665 @default.
• W2565656247 creator A5066598802 @default.
• W2565656247 date "2010-11-19" @default.
• W2565656247 modified "2023-09-30" @default.
• W2565656247 title "Ofatumumab, a Fully Human Monoclonal Antibody Targeting CD20, Demonstrates Activity Against and Potentiates the Anti-Tumor Activity of Chemotherapy Agents In Rituximab-Sensitive Cell Lines (RSCL), Rituximab-Resistant Cell Lines (RRCL), Lymphoma Xenografts, and Primary Tumor Cells Derived From Patients with B-Cell Non-Hodgkin Lymphoma (NHL)" @default.
• W2565656247 doi "https://doi.org/10.1182/blood.v116.21.3917.3917" @default.
• W2565656247 hasPublicationYear "2010" @default.
• W2565656247 type Work @default.
• W2565656247 sameAs 2565656247 @default.
• W2565656247 citedByCount "1" @default.
• W2565656247 countsByYear W25656562472021 @default.
• W2565656247 crossrefType "journal-article" @default.
• W2565656247 hasAuthorship W2565656247A5001862108 @default.
• W2565656247 hasAuthorship W2565656247A5003033577 @default.
• W2565656247 hasAuthorship W2565656247A5024574848 @default.
• W2565656247 hasAuthorship W2565656247A5025865972 @default.
• W2565656247 hasAuthorship W2565656247A5028606740 @default.
• W2565656247 hasAuthorship W2565656247A5038651665 @default.
• W2565656247 hasAuthorship W2565656247A5066598802 @default.
• W2565656247 hasConcept C109316439 @default.
• W2565656247 hasConcept C126322002 @default.
• W2565656247 hasConcept C159654299 @default.
• W2565656247 hasConcept C18031839 @default.
• W2565656247 hasConcept C202751555 @default.
• W2565656247 hasConcept C203014093 @default.
• W2565656247 hasConcept C2776694085 @default.
• W2565656247 hasConcept C2776755627 @default.
• W2565656247 hasConcept C2778384904 @default.
• W2565656247 hasConcept C2778714382 @default.
• W2565656247 hasConcept C2779015954 @default.
• W2565656247 hasConcept C2779263901 @default.
• W2565656247 hasConcept C2779338263 @default.
• W2565656247 hasConcept C2780653079 @default.
• W2565656247 hasConcept C2780790343 @default.
• W2565656247 hasConcept C40677261 @default.
• W2565656247 hasConcept C502942594 @default.
• W2565656247 hasConcept C542903549 @default.
• W2565656247 hasConcept C55493867 @default.
• W2565656247 hasConcept C71924100 @default.
• W2565656247 hasConcept C86803240 @default.
• W2565656247 hasConcept C98274493 @default.
• W2565656247 hasConceptScore W2565656247C109316439 @default.
• W2565656247 hasConceptScore W2565656247C126322002 @default.
• W2565656247 hasConceptScore W2565656247C159654299 @default.
• W2565656247 hasConceptScore W2565656247C18031839 @default.
• W2565656247 hasConceptScore W2565656247C202751555 @default.
• W2565656247 hasConceptScore W2565656247C203014093 @default.
• W2565656247 hasConceptScore W2565656247C2776694085 @default.
• W2565656247 hasConceptScore W2565656247C2776755627 @default.
• W2565656247 hasConceptScore W2565656247C2778384904 @default.
• W2565656247 hasConceptScore W2565656247C2778714382 @default.
• W2565656247 hasConceptScore W2565656247C2779015954 @default.
• W2565656247 hasConceptScore W2565656247C2779263901 @default.
• W2565656247 hasConceptScore W2565656247C2779338263 @default.
• W2565656247 hasConceptScore W2565656247C2780653079 @default.
• W2565656247 hasConceptScore W2565656247C2780790343 @default.
• W2565656247 hasConceptScore W2565656247C40677261 @default.
• W2565656247 hasConceptScore W2565656247C502942594 @default.
• W2565656247 hasConceptScore W2565656247C542903549 @default.
• W2565656247 hasConceptScore W2565656247C55493867 @default.
• W2565656247 hasConceptScore W2565656247C71924100 @default.
• W2565656247 hasConceptScore W2565656247C86803240 @default.
• W2565656247 hasConceptScore W2565656247C98274493 @default.
• W2565656247 hasLocation W25656562471 @default.
• W2565656247 hasOpenAccess W2565656247 @default.
• W2565656247 hasPrimaryLocation W25656562471 @default.
• W2565656247 hasRelatedWork W1448205674 @default.
• W2565656247 hasRelatedWork W1593874097 @default.
• W2565656247 hasRelatedWork W2132467087 @default.
• W2565656247 hasRelatedWork W2148775041 @default.
• W2565656247 hasRelatedWork W2328723989 @default.
• W2565656247 hasRelatedWork W2509642163 @default.
• W2565656247 hasRelatedWork W2557644565 @default.
• W2565656247 hasRelatedWork W2559474754 @default.
• W2565656247 hasRelatedWork W2566602522 @default.
• W2565656247 hasRelatedWork W2574419435 @default.
• W2565656247 hasRelatedWork W2576882379 @default.
• W2565656247 hasRelatedWork W2581204320 @default.
• W2565656247 hasRelatedWork W2582321885 @default.
• W2565656247 hasRelatedWork W2592318309 @default.
• W2565656247 hasRelatedWork W2607445637 @default.
• W2565656247 hasRelatedWork W2741978170 @default.
• W2565656247 hasRelatedWork W2785259311 @default.
• W2565656247 hasRelatedWork W2979668219 @default.
• W2565656247 hasRelatedWork W2994379879 @default.
• W2565656247 hasRelatedWork W3096697302 @default.
• W2565656247 isParatext "false" @default.
• W2565656247 isRetracted "false" @default.
• W2565656247 magId "2565656247" @default.
• W2565656247 workType "article" @default.